Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Large Increase in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 140,557 shares, an increase of 67.0% from the September 30th total of 84,156 shares. Based on an average daily trading volume, of 4,969,953 shares, the days-to-cover ratio is currently 0.0 days. Currently, 40.7% of the company’s stock are short sold.

Analysts Set New Price Targets

Several analysts have recently commented on JAGX shares. Wall Street Zen raised Jaguar Animal Health to a “sell” rating in a research note on Saturday, October 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.

Jaguar Animal Health Stock Down 45.7%

JAGX opened at $0.88 on Tuesday. The company has a quick ratio of 0.40, a current ratio of 0.69 and a debt-to-equity ratio of 0.35. The stock has a market cap of $299,200.00, a price-to-earnings ratio of -0.00 and a beta of -0.11. Jaguar Animal Health has a twelve month low of $0.81 and a twelve month high of $1,102.50. The company’s 50-day moving average price is $6.22 and its two-hundred day moving average price is $121.34.

Jaguar Animal Health (NASDAQ:JAGX) last announced its quarterly earnings data on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, topping the consensus estimate of ($782.25) by $766.55. The firm had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $4.24 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and commercializing plant-based pharmaceuticals for gastrointestinal disorders in animals. Its research programs are designed to address conditions affecting companion animals, livestock and other animal species, with an emphasis on therapies that support intestinal function and overall animal health.

The company’s lead product is Canalevia-CA1, a prescription product containing crofelemer. Canalevia-CA1 received conditional approval from the U.S.